Hiddo J L Heerspink Selected Research

Symporters

1/2022	Kidney and heart failure outcomes associated with SGLT2 inhibitor use.
12/2021	Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
1/2021	A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors.
1/2021	Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease.
1/2021	New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.
1/2021	Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure.
1/2021	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
1/2021	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
11/2020	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
10/2020	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiddo J L Heerspink Research Topics

Disease

136	Type 2 Diabetes Mellitus (MODY) 10/2022 - 01/2016
73	Chronic Renal Insufficiency 10/2022 - 04/2016
66	Albuminuria 06/2022 - 01/2016
42	Heart Failure 10/2022 - 09/2016
36	Diabetic Nephropathies (Diabetic Nephropathy) 05/2022 - 01/2016
29	Kidney Diseases (Kidney Disease) 10/2022 - 01/2016
28	Renal Insufficiency (Renal Failure) 04/2022 - 01/2018
19	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 04/2016
18	Body Weight (Weight, Body) 01/2022 - 01/2017
16	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 04/2016
8	Inflammation (Inflammations) 10/2022 - 01/2018
8	Proteinuria 11/2021 - 12/2017
7	Disease Progression 06/2022 - 01/2016
7	Myocardial Infarction 01/2022 - 09/2016
7	Diabetes Mellitus 01/2022 - 01/2016
5	Infections 04/2022 - 09/2016
5	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 09/2016
5	Hypertension (High Blood Pressure) 01/2022 - 12/2017
5	Stroke (Strokes) 01/2022 - 09/2016
4	Hyperkalemia 10/2022 - 01/2020
4	Obesity 01/2022 - 10/2016
3	Overweight 01/2022 - 01/2021
3	Neoplasms (Cancer) 01/2021 - 01/2020
3	IGA Glomerulonephritis (IGA Nephropathy) 01/2021 - 01/2021
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 01/2016
2	COVID-19 04/2022 - 01/2022
2	Edema (Dropsy) 12/2021 - 09/2017
2	Anemia 08/2021 - 12/2020
2	Glomerulonephritis 01/2021 - 01/2021
2	Ketosis 01/2021 - 01/2021
2	Acute Coronary Syndrome 01/2020 - 11/2018
2	Hypotension (Low Blood Pressure) 01/2020 - 01/2020

Drug/Important Bio-Agent (IBA)

55	CreatinineIBA 10/2022 - 04/2016
51	dapagliflozinIBA 08/2022 - 05/2017
46	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 10/2017
45	SodiumIBA 10/2022 - 09/2016
44	AlbuminsIBA 10/2022 - 04/2016
40	Sodium-Glucose Transporter 2 InhibitorsIBA 10/2022 - 09/2016
31	CanagliflozinIBA 10/2022 - 01/2017
26	Biomarkers (Surrogate Marker)IBA 05/2022 - 01/2016
23	Sodium-Glucose Transport ProteinsIBA 10/2022 - 09/2016
20	SymportersIBA 01/2022 - 10/2017
19	Pharmaceutical PreparationsIBA 11/2021 - 11/2016
15	AtrasentanIBA 01/2022 - 01/2017
11	empagliflozinIBA 06/2022 - 09/2016
9	DiureticsIBA 10/2022 - 09/2017
9	Hemoglobins (Hemoglobin)IBA 04/2022 - 09/2016
7	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2019
6	PotassiumIBA 10/2022 - 01/2020
6	Endothelin Receptor AntagonistsIBA 01/2022 - 11/2019
6	Proteins (Proteins, Gene)FDA Link 08/2021 - 01/2019
5	Mineralocorticoid Receptor AntagonistsIBA 10/2022 - 01/2018
5	Uric Acid (Urate)IBA 01/2022 - 01/2018
5	Angiotensin Receptor AntagonistsIBA 11/2019 - 01/2016
4	Spironolactone (Aldactone)FDA LinkGeneric 03/2022 - 01/2018
4	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 11/2018
4	HDL LipoproteinsIBA 01/2022 - 01/2020
4	HDL CholesterolIBA 01/2022 - 01/2020
4	Losartan (Cozaar)FDA LinkGeneric 01/2021 - 01/2016
4	Exenatide (Byetta)FDA Link 01/2021 - 10/2019
4	CholesterolIBA 01/2020 - 01/2017
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2019 - 04/2016
3	finerenoneIBA 06/2022 - 10/2020
3	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 10/2018
3	Liraglutide FDA Link 01/2022 - 11/2020
3	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 01/2018
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2022 - 01/2021
3	DiamondIBA 01/2022 - 01/2020
3	LDL CholesterolIBA 01/2022 - 01/2021
3	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2018
3	Lipoproteins (Lipoprotein)IBA 01/2022 - 01/2020
3	LinagliptinIBA 09/2021 - 01/2017
3	Serum AlbuminIBA 08/2021 - 01/2020
3	Biological ProductsIBA 02/2019 - 01/2019
2	Hormones (Hormone)IBA 05/2022 - 01/2019
2	Eplerenone (Inspra)FDA LinkGeneric 03/2022 - 01/2022
2	Type I Tumor Necrosis Factor ReceptorsIBA 01/2022 - 01/2019
2	MineralsIBA 01/2022 - 01/2019
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2022 - 01/2022
2	Insulin (Novolin)FDA Link 01/2022 - 01/2022
2	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022 - 01/2021
2	Dipeptidyl-Peptidase IV InhibitorsIBA 09/2021 - 01/2020
2	Immunoglobulin A (IgA)IBA 01/2021 - 01/2021
2	Peptides (Polypeptides)IBA 01/2021 - 01/2018
2	Gliclazide (Diamicron)IBA 01/2021 - 01/2020
2	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 01/2021 - 01/2019
2	Phosphates (Orthophosphate)IBA 01/2020 - 01/2019
2	glimepiride (Amarel)FDA LinkGeneric 01/2020 - 01/2017
2	Atorvastatin (Lipitor)FDA Link 12/2019 - 10/2019
2	Rosuvastatin Calcium (Crestor)FDA Link 12/2019 - 10/2019
2	Endothelin A ReceptorIBA 11/2019 - 01/2018
2	bardoxolone methylIBA 10/2019 - 01/2018
2	Metformin (Glucophage)FDA LinkGeneric 10/2019 - 01/2017
2	IncretinsIBA 01/2019 - 01/2019

Therapy/Procedure

37	Therapeutics 06/2022 - 01/2016
6	Precision Medicine 05/2022 - 10/2018
4	Renal Replacement Therapy (Therapies, Renal Replacement) 04/2022 - 01/2018
3	Transplantation 01/2022 - 01/2019
3	Kidney Transplantation 11/2019 - 01/2018
2	Secondary Prevention 01/2021 - 01/2019